Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28734482 | 0.83 | HSD17B10 (0.37) | HSD17B10KDM4EALDH1A1TDP1MEN1 | |
| SCHEMBL4915224 | 0.82 | GNAI3 (0.44) | HSD17B10KDM4EHTR1AGNAI3GNAO1 | |
| SCHEMBL21440365 | 0.81 | DRD2 (0.39) | KDM4EMAPTTAAR1ALDH1A1HTT | |
| SCHEMBL3947375 | 0.81 | DRD2 (0.44) | HSD17B10HRH3GAAGNAI3GNAO1 | |
| SCHEMBL7767622 | 0.81 | HTR1A (0.45) | HSD17B10KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL28686662 | 0.80 | CARM1 (0.38) | HSD17B10KDM4EALDH1A1HRH3 | |
| SCHEMBL6848265 | 0.80 | HSD17B10 (0.35) | HSD17B10KDM4EMAPTALDH1A1TDP1 | |
| SCHEMBL4901796 | 0.80 | GNAI3 (0.52) | HSD17B10KDM4EGAAHTR1AGNAI3 | |
| Hydrochloric Acid SCHEMBL29165064 | 0.80 | GNAI3 (0.47) | HSD17B10KDM4EHTR1AGNAI3GNAO1 | |
| SCHEMBL1783126 | 0.80 | HSD11B1 (0.41) | HSD17B10KDM4EALDH1A1TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| EP-0539372-A1 | THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | OGFRL1, OPRL1, ORMDL3 | HSD17B10 2560/4885KDM4E 4525/4885MAPT 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.